Randomized phase II trial of nanoparticle albumin-bound paclitaxel in three dosing schedules with bevacizumab as first-line therapy for HER2-negative metastatic breast cancer (MBC) Meeting Abstract
| Authors: | Conlin, A. K.; Hudis, C. A.; Bach, A.; Moynahan, M.; Lake, D.; Forero-Torres, A.; Wright, G.; Hackney, M.; Clawson, A.; Seidman, A. D. |
| Abstract Title: | Randomized phase II trial of nanoparticle albumin-bound paclitaxel in three dosing schedules with bevacizumab as first-line therapy for HER2-negative metastatic breast cancer (MBC) |
| Meeting Title: | 45th Annual Meeting of the American Society of Clinical Oncology (ASCO) |
| Journal Title: | Journal of Clinical Oncology |
| Volume: | 27 |
| Issue: | 15 Suppl. |
| Meeting Dates: | 2009 May 29-Jun 2 |
| Meeting Location: | Orlando, FL |
| ISSN: | 0732-183X |
| Publisher: | American Society of Clinical Oncology |
| Date Published: | 2009-05-20 |
| Start Page: | 42s |
| Language: | English |
| ACCESSION: | WOS:000276606601485 |
| PROVIDER: | wos |
| DOI: | 10.1200/jco.2009.27.15_suppl.1006 |
| Notes: | Meeting Abstract: 1006 -- Source: Wos |
Altmetric
Citation Impact
BMJ Impact Analytics
